Skip to main content
. 2010 Sep 10;17(1-2):12–20. doi: 10.2119/molmed.2010.00103

Figure 4.

Figure 4

Kaplan–Meier survival analysis of H3K27me3 expression in subsets of HCC patients in different stages (log-rank test). (A) Stage II, probability of survival of stage II patients with HCC in the testing cohort: low expression, n = 33; high expression, n = 27. Stage III, probability of survival of patients with stage III HCC in the testing cohort: low expression, n = 24; high expression, n = 73. Stage IV, probability of survival of stage IV patients with HCC in the testing cohort: low expression, n = 8; high expression, n = 19. (B) Stage II, probability of survival of stage II patients with HCC in the validation cohort: low expression, n = 29; high expression, n = 21. Stage III, probability of survival of stage III patients with HCC in the validation cohort: low expression, n = 9; high expression, n = 41. Stage IV, probability of survival of stage IV patients with HCC in the validation cohort: low expression, n = 6; high expression, n = 8.